Philippe Armand, MD, PhD

Dr. Armand leads the Lymphoma Division at Dana-Farber Cancer Institute. He oversees a diverse portfolio of clinical research across different lymphoma subtypes and types of therapy. Current areas of high priority include:

• immunotherapy, especially around the use of engineered cellular therapy (for example chimeric antigen receptor T-cell therapy), immune cell-engaging antibodies, and checkpoint blockade;
• the development of personalized targeted therapy, through the application of modern genomic understanding of tumors, the creation of novel assays to characterize individual patients’ genomic profile, and the validation of strategies to match a given tumor profile to a given therapy;
• novel therapeutics in T-cell lymphoma, based on a deeper understanding of their molecular underpinnings;
• novel therapeutics and novel combinations in CLL, based on integrating clinical data, large-scale and multifaceted laboratory investigations of clinical samples, and clinical trial collaborative structures.

Across these areas, the driving principle of research in the Division is to apply cutting-edge scientific understanding of lymphoma to support the development of clinical trials testing novel therapeutic approaches; while in turn using data and samples from these trials to support laboratory research, advance the scientific understanding and inform the next generation of studies.